Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas... Show more
Curis, Inc. is a clinical-stage biotechnology company concentrated on emavusertib, an orally administered small-molecule inhibitor of IRAK4 (interleukin-1 receptor-associated kinase 4) and FLT3. The drug is being developed across three hematologic settings: relapsed/refractory PCNSL, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This single-asset focus creates a sharply defined investment profile: the entire market positioning of the company hinges on how emavusertib performs in a handful of well-defined, hard-to-treat blood cancers.
From a competitive standpoint, an oral, brain-penetrant therapy that can be combined with existing BTK (Bruton's tyrosine kinase) inhibitors such as ibrutinib and zanubrutinib occupies a differentiated niche. In PCNSL, an ultra-orphan indication with limited approved options, early data showing a 100% objective response rate in BTK-inhibitor-naive patients has underpinned the regulatory discussion around an accelerated filing. Orphan Drug Designations from both the FDA and the European Commission strengthen the medium-term commercial and regulatory case. However, the company's market positioning is structurally narrow, and its innovation cycle is tied to a single mechanism, leaving limited diversification if a key readout disappoints.
The most consequential near-term event is the expected initial data from the TakeAim CLL Phase 2 study, anticipated around the December 2026 timeframe. This readout could validate the thesis that adding emavusertib to a BTK inhibitor converts partial responses into deeper remissions and potentially undetectable disease. A second pivotal catalyst is the planned PCNSL program update in the first half of 2027, where the primary endpoint of overall response rate in a single-arm registrational design could support accelerated approval submissions in both the U.S. and Europe.
Beyond clinical data, capital allocation and financing structure remain active catalysts. The company's runway depends in part on milestone-linked warrant exercises, and management has stated that additional funding will be required to complete development through approval and commercialization. Analyst activity has reflected growing caution rather than enthusiasm: H.C. Wainwright lowered its price target to $6 from $43 in November 2026, while JonesTrading reiterated a Buy but reduced its target to $5 from $20. Consensus remains a Buy across the small covering group, but the direction of target revisions has been downward, signaling that expectations around valuation and execution risk have been recalibrated.
As a pre-revenue, development-stage biotech, Curis is less directly sensitive to interest rates, inflation, and consumer demand cycles than a commercial enterprise, but it is highly exposed to financing conditions and the cost of capital. Higher-for-longer interest rates and tighter biotech funding markets can raise the cost and dilution of future equity raises, directly influencing runway assumptions. Conversely, a more accommodative funding environment could ease capital-access risk.
Regulatory climate is the dominant macro force. Constructive engagement with the FDA and the European Medicines Agency around accelerated and conditional pathways for ultra-orphan indications lowers development timelines and cost. The broader industry shift toward targeted, orally available oncology agents and biomarker-driven combination strategies is structurally supportive of Curis's mechanism-focused approach, even as large-cap competitors command greater resources across overlapping hematology markets.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the coming week or month. It is designed to help users identify developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking a catalyst-driven, development-stage name such as CRIS, tools like this can add a technical layer to fundamental analysis.
Heading into 2026 and beyond, Curis's trajectory will be defined by execution across three fronts. First, the December 2026 CLL readout and the first-half 2027 PCNSL update represent the clearest near-term value inflection points; positive data would meaningfully de-risk the pipeline and strengthen the regulatory case. Second, regulatory strategy will be pivotal. Securing an accelerated approval path in PCNSL would transition the company from a clinical story toward a potential commercial launch and provide a more durable revenue base, replacing the Erivedge royalty stream that was divested in late 2025.
Third, capital structure and cost discipline remain central long-term themes. Research and development expenses have been reduced, and management has guided that current resources could fund operations into the second half of 2027, but additional financing is still expected before commercialization. The cost-structure evolution will depend on trial enrollment pace and whether milestone-linked warrants are exercised. While consensus analyst expectations still project substantial revenue growth over the coming years, published price targets span a wide range and have been revised lower, reflecting genuine uncertainty about clinical outcomes, dilution, and execution. Investors watching this story should focus on data catalysts, regulatory progress, and financing developments rather than short-term price movement.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with ORMP. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then ORMP could also see price increases.
| Ticker / NAME | Correlation To CRIS | 1D Price Change % | ||
|---|---|---|---|---|
| CRIS | 100% | -23.59% | ||
| ORMP - CRIS | 34% Loosely correlated | -5.14% | ||
| VTGN - CRIS | 33% Loosely correlated | -6.47% | ||
| AMRN - CRIS | 30% Poorly correlated | N/A | ||
| DMRA - CRIS | 30% Poorly correlated | +5.74% | ||
| ALGS - CRIS | 30% Poorly correlated | -3.85% | ||
More | ||||
a drug company
Industry Biotechnology
CRIS's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 70 similar instances where the Aroon Indicator showed a similar pattern. In 64 of the 70 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +40.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for CRIS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In 70 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
CRIS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRIS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (3.596). P/E Ratio (0.248) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.